Additional Studies with Antibody-Drug Conjugates in NSCLC

Video

Two experts discuss additional studies with antibody-drug conjugates targeting non-small cell lung cancer and the impact of their data on therapeutic options for the disease.

Related Videos
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Raj Singh, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
George R. Simon, MD, FACP, FCCP
Ashish Saxena, MD, PhD
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Related Content
Raj Singh, MD, of The Ohio State University Comprehensive Cancer Center––James

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
Subcutaneous Atezolizumab in Cancer: © vxnaghiyev - stock.adobe.com

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article